ASTELLAS PHARMA UNSP.ADR (YPHA) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.36x

ASTELLAS PHARMA UNSP.ADR (YPHA) has a Cash Flow Reinvestment Rate of 0.36x as of March 2025, reinvesting €70.25 Billion (capex €57.33 Billion plus investments €12.92 Billion) from operating cash flow of €194.51 Billion. Check ASTELLAS PHARMA UNSP.ADR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.36x
(Capex + Investments) / Operating CF

Total Reinvested

€70.25 Billion
Capex + Investments

Operating Cash Flow

€194.51 Billion
EUR

Capital Expenditures

€57.33 Billion
EUR

ASTELLAS PHARMA UNSP.ADR Cash Flow Reinvestment Rate (2022–2025)

Historical reinvestment intensity for ASTELLAS PHARMA UNSP.ADR across 4 annual periods. Explore ASTELLAS PHARMA UNSP.ADR (YPHA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for ASTELLAS PHARMA UNSP.ADR (2022–2025)

Year-by-year capital reinvestment analysis for ASTELLAS PHARMA UNSP.ADR. For live market cap and broader valuation context, see ASTELLAS PHARMA UNSP.ADR stock valuation.

Year Reinvestment Rate Total Reinvested (EUR) Operating CF Capex YoY Change
2025 0.36x €70.25 Billion €194.51 Billion €57.33 Billion ▼ -24.5%
2024 0.48x €82.50 Billion €172.47 Billion €82.50 Billion ▲ +55.0%
2023 0.31x €101.17 Billion €327.77 Billion €88.54 Billion ▼ -3.1%
2022 0.32x €82.02 Billion €257.44 Billion €76.45 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow